Modified antibody-albumin nanoparticle complexes for cancer treatment
AssigneeMayo Foundation for Medical Education and Research
InventorsSvetomir N. Markovic, Wendy K Nevala, John Thomas Butterfield, Daniel Joseph Knauer
Life of this patent
Estimating the term…
Abstract
Described herein are compositions of modified binding agents and modified carrier proteins, as well as nanoparticle complexes comprising modified binding agents and modified carrier proteins with optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic.
Claims34
A composition comprising nanoparticie complexes, wherein each of the nanoparticle complexes comprises:
- a carrier protein having a modified polypeptide sequence that was modified to comprise at least one antibody-binding motif;
- antibodies, each antibody having an antigen-binding domain;
- and optionally a therapeutic agent;
- wherein the nanoparticle complexes have binding specificity for the antigen in vivo.
2-3. (canceled)
5-9. (canceled)
(canceled)
18-22. (canceled)
(canceled)
26-28. (canceled)
A method for making a nanoparticle complex, the method comprising incubating a carrier protein having a modified polypeptide sequence that was modified to comprise at least one antibody-binding motif with an antibody.
(canceled)
(canceled)
37-39. (canceled)
A carrier protein having a modified polypeptide sequence that was modified to comprise at least one antibody-binding motif.
43-45. (canceled)
A method for making a modified carrier protein, said method comprising providing a carrier protein having a polypeptide sequence and modifying the polypeptide sequence to comprise an antibody-binding motif, wherein the modified carrier protein has a higher affinity for binding to an antibody than the carrier protein before modification.
Dependencies are inferred from the claim text.